AngioDynamics, Inc. — Form 8-K Summary
Reporting period: Fiscal first quarter ended August 31, 2026. The 8-K was dated October 8, 2026 and reports that the company issued a results press release and furnished presentation slides.
Financial results and comparisons
The supplied filing text does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial results. It also does not provide comparable-period figures or quantify changes versus the prior year. The referenced press release (Exhibit 99.1) and presentation (Exhibit 99.2) are not included in the supplied text.
Outlook, risks, and filing details
No specific guidance or outlook figures are provided in the supplied text. The company cautions that forward-looking statements are subject to risks, including product development and market acceptance, competition, regulatory actions, clinical-trial outcomes, litigation, recalls and product liability, economic conditions, inflation, tariffs, labor and supply-chain challenges, pricing pressures, foreign-exchange movements, and execution of strategic initiatives. It refers investors to risk factors in its Form 10-K for the year ended May 31, 2026.
The results and presentation are furnished under Items 2.02 and 7.01 and are not deemed filed for purposes of Exchange Act Section 18 or incorporated by reference, except as expressly specified.
Key facts to verify
- Obtain Exhibits 99.1 and 99.2 for the actual quarterly results, year-over-year comparisons, and any guidance.
- Review the company’s Form 10-K for the year ended May 31, 2026, for detailed risk factors and financial context.